EA202191699A1 - Способы для охарактеризования дисульфидных связей - Google Patents
Способы для охарактеризования дисульфидных связейInfo
- Publication number
- EA202191699A1 EA202191699A1 EA202191699A EA202191699A EA202191699A1 EA 202191699 A1 EA202191699 A1 EA 202191699A1 EA 202191699 A EA202191699 A EA 202191699A EA 202191699 A EA202191699 A EA 202191699A EA 202191699 A1 EA202191699 A1 EA 202191699A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- drug product
- protein drug
- peptide standards
- disulfide bonds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012512 characterization method Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 229940126534 drug product Drugs 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Предлагаются композиции и способы для анализа дисульфидных связей. Иллюстративный способ включает в себя приготовление пептидных стандартов, не имеющих дисульфидных связей, пептидных стандартов с скремблированными дисульфидными связями, и пептидных стандартов с нативными дисульфидными связями, в соответствии с последовательностью области белкового лекарственного продукта, которая включает в себя дисульфидную связь, расщепление образца белкового лекарственного продукта на пептиды, разделение пептидов белкового лекарственного продукта, анализ пептидов белкового лекарственного продукта и пептидных стандартов, идентификацию пептидов с скремблированными и нативными дисульфидными связями по времени удерживания, и количественное определение уровня пептидов с скремблированными дисульфидными связями.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792994P | 2019-01-16 | 2019-01-16 | |
| PCT/US2020/013907 WO2020150491A1 (en) | 2019-01-16 | 2020-01-16 | Methods for characterizing disulfide bonds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191699A1 true EA202191699A1 (ru) | 2021-10-11 |
Family
ID=69570836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191841A EA202191841A1 (ru) | 2019-01-16 | 2020-01-16 | Способы для идентификации свободных тиолов в белках |
| EA202191699A EA202191699A1 (ru) | 2019-01-16 | 2020-01-16 | Способы для охарактеризования дисульфидных связей |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191841A EA202191841A1 (ru) | 2019-01-16 | 2020-01-16 | Способы для идентификации свободных тиолов в белках |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11674968B2 (ru) |
| EP (3) | EP3857237B1 (ru) |
| JP (2) | JP2022517721A (ru) |
| KR (2) | KR20210114927A (ru) |
| CN (3) | CN113272650A (ru) |
| AU (2) | AU2020208396A1 (ru) |
| BR (2) | BR112021009544A2 (ru) |
| CA (2) | CA3116735A1 (ru) |
| DK (1) | DK3857237T3 (ru) |
| EA (2) | EA202191841A1 (ru) |
| ES (1) | ES2942024T3 (ru) |
| FI (1) | FI3857237T3 (ru) |
| HU (1) | HUE061783T2 (ru) |
| IL (2) | IL284471A (ru) |
| MX (2) | MX2021008589A (ru) |
| PL (1) | PL3857237T3 (ru) |
| SG (2) | SG11202104103XA (ru) |
| WO (2) | WO2020150492A1 (ru) |
| ZA (2) | ZA202102546B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191841A1 (ru) | 2019-01-16 | 2021-10-07 | Ридженерон Фармасьютикалз, Инк. | Способы для идентификации свободных тиолов в белках |
| MX2023007151A (es) * | 2020-12-20 | 2023-06-28 | Regeneron Pharma | Metodos para la identificacion de disulfuros aleatorizados en biomoleculas. |
| US20240060988A1 (en) * | 2021-02-25 | 2024-02-22 | Dr. Reddy’S Laboratories Limited | Thiol variants and analytical methods thereof |
| CN113189254B (zh) * | 2021-05-08 | 2021-11-16 | 北京工商大学 | 一种基于白酒中挥发性硫醇化合物的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| JP3727317B2 (ja) | 2002-03-08 | 2005-12-14 | エイエスエムエル ネザランドズ ベスローテン フエンノートシャップ | リソグラフィに使用するためのマスク、マスクを作成する方法、リソグラフィ装置、およびデバイス製造方法 |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009018411A1 (en) | 2007-07-31 | 2009-02-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human cd20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2799540A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| MY158130A (en) | 2010-10-06 | 2016-08-30 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP2648751A4 (en) * | 2010-12-09 | 2015-04-15 | Bayer Healthcare Llc | DIMERE MOLECULAR COMPLEXES WITH FREE CYSTEIN RESTANTS AND CONJUGATES THEREOF |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| EP2807190B1 (en) | 2012-01-23 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| US9835629B2 (en) | 2012-05-18 | 2017-12-05 | Pierce Biotechnology, Inc. | Methods and reagents for biomolecule labeling, enrichment and gentle elution |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| CA2881679C (en) | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AU2014240101B2 (en) | 2013-03-15 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| BR112016020752B1 (pt) | 2014-03-11 | 2023-11-14 | Regeneron Pharmaceuticals, Inc | Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| WO2016018978A1 (en) | 2014-07-29 | 2016-02-04 | Mayo Foundation For Medical Education And Research | Quantifying monoclonal antibody therapeutics by lc-ms/ms |
| WO2016044337A1 (en) | 2014-09-16 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| CN108627647B (zh) * | 2017-03-24 | 2020-06-19 | 四川大学 | 一种翻译后修饰蛋白质组学的检测和定量方法 |
| CN109142561A (zh) * | 2018-07-17 | 2019-01-04 | 上海师范大学 | 同时定量蛋白质丰度与半胱氨酸氧化水平的方法及其应用 |
| EA202191841A1 (ru) | 2019-01-16 | 2021-10-07 | Ридженерон Фармасьютикалз, Инк. | Способы для идентификации свободных тиолов в белках |
-
2020
- 2020-01-16 EA EA202191841A patent/EA202191841A1/ru unknown
- 2020-01-16 CN CN202080006660.4A patent/CN113272650A/zh active Pending
- 2020-01-16 BR BR112021009544-6A patent/BR112021009544A2/pt unknown
- 2020-01-16 DK DK20706372.8T patent/DK3857237T3/da active
- 2020-01-16 CN CN202310621246.XA patent/CN117110492A/zh active Pending
- 2020-01-16 HU HUE20706372A patent/HUE061783T2/hu unknown
- 2020-01-16 KR KR1020217016167A patent/KR20210114927A/ko not_active Application Discontinuation
- 2020-01-16 CA CA3116735A patent/CA3116735A1/en active Pending
- 2020-01-16 CA CA3116732A patent/CA3116732A1/en active Pending
- 2020-01-16 EP EP20706372.8A patent/EP3857237B1/en active Active
- 2020-01-16 AU AU2020208396A patent/AU2020208396A1/en active Pending
- 2020-01-16 JP JP2021532315A patent/JP2022517721A/ja active Pending
- 2020-01-16 SG SG11202104103XA patent/SG11202104103XA/en unknown
- 2020-01-16 PL PL20706372.8T patent/PL3857237T3/pl unknown
- 2020-01-16 SG SG11202104237YA patent/SG11202104237YA/en unknown
- 2020-01-16 EP EP20704983.4A patent/EP3857236A1/en active Pending
- 2020-01-16 BR BR112021009543-8A patent/BR112021009543A2/pt unknown
- 2020-01-16 AU AU2020208395A patent/AU2020208395A1/en active Pending
- 2020-01-16 US US16/745,020 patent/US11674968B2/en active Active
- 2020-01-16 WO PCT/US2020/013910 patent/WO2020150492A1/en unknown
- 2020-01-16 US US16/745,006 patent/US11579150B2/en active Active
- 2020-01-16 JP JP2021532314A patent/JP2022517720A/ja not_active Withdrawn
- 2020-01-16 MX MX2021008589A patent/MX2021008589A/es unknown
- 2020-01-16 CN CN202080006686.9A patent/CN113272651B/zh active Active
- 2020-01-16 ES ES20706372T patent/ES2942024T3/es active Active
- 2020-01-16 EA EA202191699A patent/EA202191699A1/ru unknown
- 2020-01-16 FI FIEP20706372.8T patent/FI3857237T3/fi active
- 2020-01-16 WO PCT/US2020/013907 patent/WO2020150491A1/en unknown
- 2020-01-16 KR KR1020217016160A patent/KR20210114926A/ko active Search and Examination
- 2020-01-16 MX MX2021008590A patent/MX2021008590A/es unknown
- 2020-01-16 EP EP23150144.6A patent/EP4220173A3/en active Pending
-
2021
- 2021-04-16 ZA ZA2021/02546A patent/ZA202102546B/en unknown
- 2021-04-16 ZA ZA2021/02547A patent/ZA202102547B/en unknown
- 2021-06-29 IL IL284471A patent/IL284471A/en unknown
- 2021-06-29 IL IL284473A patent/IL284473A/en unknown
-
2023
- 2023-01-13 US US18/154,401 patent/US12000839B2/en active Active
- 2023-05-02 US US18/142,193 patent/US20230273216A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191699A1 (ru) | Способы для охарактеризования дисульфидных связей | |
| EP4299803A3 (en) | Macromolecule analysis employing nucleic acid encoding | |
| MX2021005757A (es) | Metodos y composiciones para la secuenciacion de proteinas. | |
| CO2017007665A2 (es) | Proteínas de unión a icos | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| MX2018009339A (es) | Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas. | |
| BR112018071107A2 (pt) | composições e métodos para a detecção de proteínas da célula hospedeira | |
| MX2021011726A (es) | Escindasas modificadas, usos de las mismas y kits relacionados. | |
| EA202192850A1 (ru) | Идентификация белков клетки-хозяина | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| MY190686A (en) | Anti-vegf protein compositions and methods for producing the same | |
| BR112022000545A2 (pt) | Composições de proteína e produtos de consumo destas | |
| BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
| EA202191931A1 (ru) | Способ характеризации видимых и/или невидимых частиц в биологических препаратах | |
| MX2021014336A (es) | Caracterizacion de variantes de carga especificas del dominio de anticuerpos. | |
| WO2021236716A3 (en) | Methods, systems and kits for polypeptide processing and analysis | |
| EA201991929A1 (ru) | Способ одновременного извлечения лигнина и диоксида кремния из биомассы и эластомер, армированный смесью лигнина и диоксида кремния | |
| EA202191961A1 (ru) | Способ и система идентификации и количественного определения фрагментации антител | |
| MX2021007518A (es) | Metodo de extraccion de proteina a partir de material vegetal de cannabis. | |
| EA202090380A1 (ru) | Системы и способы для выполнения анализа гликанов в образце в режиме реального времени | |
| WO2021009669A3 (en) | A process for separation and quantitation of proteins using capillary electrophoresis | |
| EA202091916A1 (ru) | Способ и устройство расщепления бобовых | |
| CR20220065A (es) | Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc | |
| EA202192697A1 (ru) | Диафильтрация | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. |